MNOV MediciNova
- 1.310
- -0.010-0.76%
- 1.310
- 0.0000.00%
MediciNova News
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
Express News | Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (Ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
MediciNova Vice President Geoffrey O'Brien Announces Retirement
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersLixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDA
Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment
Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sc
MediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment
By Ben Glickman MediciNova said it had received a Japanese patent allowance for its treatment for macular injury linked to multiple sclerosis. The La Jolla, Calif.-based biopharmaceutical company sa
MediciNova Receives a Notice of Allowance For a New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc (NASDAQ:MNOV) today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstrac
MediciNova Announces Two Abstracts Regarding MN-001 (Tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number:
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
MediciNova Reports Positive Results for Lung Injury Treatment
MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology
MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChina SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million. MediciNova (NASDAQ:MNOV) stock inc
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersKalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $729.1 million. Jin Medical Internati
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
DelveInsight's Non-Alcoholic Fatty Liver Disease Market Insights report includes a comprehensive understanding of current treatment practices, NAFLD...
Express News | MediciNova Secures Notice Of Grant For New Patent Covering MN-166 (Ibudilast) For Treatment Of Macular Injury In China
Top Premarket Gainers
Applied UV (AUVI) shares were up over 35% premarket Friday after the company launched its patented Fighter Flex LED service. MediciNova (MNOV) stock was 29% higher following a 2.3% fall in the previou
MediciNova Announces Abstract Regarding MN-166 (Ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc. (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.
Express News | MediciNova Receives Notice Of Decision To Grant For New Patent Covering MN-166 (Ibudilast) For Treatment Of Progressive MS In Europe
Analysis
Price Target
No Data
